EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Blau Farmaceutica's enterprise value is R$2,072 Mil.
Blau Farmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was R$416 Mil. Therefore, Blau Farmaceutica's EV-to-EBITDA for today is 4.98.
The historical rank and industry rank for Blau Farmaceutica's EV-to-EBITDA or its related term are showing as below:
BSP:BLAU3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.78 Med: 10.19 Max: 18.79
Current: 4.97
During the past 8 years, the highest EV-to-EBITDA of Blau Farmaceutica was 18.79. The lowest was 4.78. And the median was 10.19.
BSP:BLAU3's EV-to-EBITDA is ranked better than 88.51% of 705
companies
in the Drug Manufacturers industry
Industry Median: 14.53
vs BSP:BLAU3: 4.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Blau Farmaceutica EV-to-EBITDA Historical Data
The historical data trend for Blau Farmaceutica's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Blau Farmaceutica's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's EV-to-EBITDA falls into.
Blau Farmaceutica's current Enterprise Value is R$2,072 Mil.
Blau Farmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$416 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Blau Farmaceutica's PE Ratio for today is calculated as:
Blau Farmaceutica's share price for today is R$10.53.
Blau Farmaceutica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Blau Farmaceutica's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Blau Farmaceutica (BSP:BLAU3) Business Description
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:BLAU3 has been successfully added to your 